Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

MACK $9.21 1.3400 +17.03%
TGTX $11.93 1.7100 +16.73%
ATRA $34.18 4.2100 +14.05%
RXDX $9.35 1.1500 +14.02%
GLYC $5.65 0.6699 +13.45%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

SNSS $0.90 -0.0485 -5.11%
GALT $2.25 -0.0900 -3.85%
CLBS $1.48 -0.0300 -1.99%
RDHL $12.55 -0.2300 -1.80%
VBLT $7.71 -0.1200 -1.53%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | Next > | Last >>

MRI Tied to More Aggressive Breast Cancer Treatment

(Medscape Medical News) Sept 24, 2015 - The use of preoperative magnetic resonance imaging (pMRI) in women with newly diagnosed breast cancer has increased by eightfold during the past 10 years in Canada's most populous province and is associated with significant increases in adverse downstream consequences, including more mastectomies, a population-based study indicates.
read article (free registration required) 

SHIVA - A Next-Generation Trial Disappoints, Provides Insights

(Medscape Medical News) Sept 23, 2015 - The first randomized trial evaluating therapy based on molecular profiling of tumors has not shown superiority over conventional therapy.
read article (free registration required) 

NICE Backs Gilead's Novel Leukaemia Drug for NHS Use

(PharmaTimes [UK]) Sept 24, 2015 - Some adults with chronic lymphocytic leukaemia could soon get routine access to Gilead's Zydelig on the National Health Service in England and Wales, after cost regulators voiced support for its use.
read article 

CTI BioPharma To Submit NDA For Pacritinib In Q4 Based Primarily On Data From Single Pivotal Persist-1 Trial

(MarketWatch) Sept 23, 2015 - CTI BioPharma Corp. today announced its plan to submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) following a productive pre-NDA meeting for pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R.
read article 

UK NHS Cancer Patients Denied Drugs Due To Inflated Prices – Experts

(The Guardian [UK]) Sept 23, 2015 - Cancer patients are being denied drugs on the NHS that could lengthen their lives because of unnecessarily exorbitant prices, say experts.
read article 

The Assault on Drug Innovation

(Wall Street Journal) Sept 22, 2015 - The political blaze over drug costs that kicked up a year ago over the Hepatitis C cure Sovaldi has moved on to therapies for more diseases—and beyond white heat too.
read article (paid subscription required) 

GSK May Get EU Green Light For New Biotech Asthma Drug This Week

(Reuters) Sept 23, 2015 - GlaxoSmithKline may get a green light from European regulators as early as this week for a new biotech medicine to treat severe asthma, boosting prospects for its struggling respiratory business.
read article 

New Weapon in Push to Lower U.S. Biotech Drug Prices

(Wall Street Journal) Sept 22, 2015 - The introduction of biosimilar drugs in the U.S., which kicked off this month with Novartis AG’s version of an Amgen Inc. blockbuster, hands health-care payers a new weapon against rising drug prices. But it could be a duller blade than they had hoped.
read article (paid subscription required) 

Clinton's Plan To Control Prescription Drug Costs Features Cap On Out-Of-Pocket Expenses

(KHN Morning Briefing) Sept 23, 2015 - Democratic presidential candidate Hillary Clinton's proposal would also allow Medicare to negotiate lower drug costs and increase federal scrutiny of pharmaceutical company pricing.
read article 

How the U.S. Could Cure Drug-Price Insanity by Peter B. Bach, MD

(Fortune) September 15, 2015 Issue - To make sure society keeps benefiting from specialty cancer drugs, we need to curb their soaring costs.
read article 

Growing Number of ASCO Members Take Action During August Congressional Recess

(ASCO in Action) Sept 22, 2015 - Twenty seven ASCO members from California to Florida participated in 30 in-district meetings during the August 2015 Congressional recess to highlight ASCO advocacy priorities related to cancer care.
read article 

Government Shutdown Showdown

(ASCO in Action) Sept 22, 2015 - With Congress facing an October 1 deadline to pass the FY16 budget or a continuing resolution to avoid a government shutdown, ASCO is urging lawmakers to reach a budget deal that will expand critical funding for the National Institutes of Health and the National Cancer Institute.
read article 

ASCO Applauds IOM Report "Improving Diagnosis in Health Care”

(ASCO) Sept 23, 2015 - ASCO applauds the Institute of Medicine’s (IOM) new report, Improving Diagnosis in Health Care, released yesterday, and IOM’s continued efforts to improve the quality and safety of healthcare in the United States.
read press release 

HHS Releases 5-Year Health IT Strategic Plan

(ACCC) Sept 22, 2015 - On Sept. 21, 2015, the U.S. Department of Health and Human Services (HHS) released the Federal Health Strategic Plan 2015-2020, the final version of its 5-year plan for encouraging health IT use among physicians and hospitals.
read article 

November 19, 2015: Meeting of the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee Meeting Announcement

( Sept 22, 2015 - Information will be presented to gauge investigator interest in exploring potential pediatric development plans for two products in various stages of development for adult cancer indications. The products under consideration are: (1) ABT-414, submitted by AbbVie, Inc., and (2) Lenvatinib, submitted by Eisai, Inc.
read article 

Cure Forward Launches Precision Medicine Engagement Platform for Cancer Patients

(MarketWatch) Sept 22, 2015 - Multi-sided technology platform developed to make genomic information usable for consumers and accelerate clinical trial enrollment.
read article 

Counsyl’s New Expanded Inherited Cancer Screen Allows Clinicians to Identify Women at Elevated Cancer Risk Who Would have Otherwise Been Missed

(Yahoo! Finance) Sept 22, 2015 - Customizable 22-gene cancer panel, on-demand counseling, and streamlined workflow enable clinicians to test and identify more at-risk patients and provide better preventive care.
read article 

New Research Robot Tests Cancer Combinations

(PharmaTimes [UK]) Sept 23, 2015 - A new smart research robot may be able to accelerate research on cancer medicines by finding optimal treatment combinations.
read article 

Medtronic Testing Lung Cancer Detector (Video)

(Minneapolis/St. Paul Business Journal) Sept 22, 2015 - Medtronic Inc. has launched a 2,500-patient global study of its SuperDimension system for diagnosing lung cancer.
read article 

Vascular Biogenics Surges for Third Day on Cancer Drug Prospect

(Bloomberg) Sept 22, 2015 - Vascular Biogenics Ltd., the Israeli biotechnology company that is developing cancer treatments, rallied for a third day on bets it will show promising results from clinical drug trials at a medical conference in Europe this weekend.
read article 

Merck's Keytruda Tested in Four New Cancers

(Pharmaphorum [UK]) Sept 22, 2015 - US drugmaker Merck & Co will present data on the use of its PD-1 inhibitor Keytruda in four new cancer types later this week as it jostles for territory in the fast-growing immuno-oncology sector.
read article 

What Cancer Doctors Don’t Know About Cancer Drugs

(Wall Street Journal) Sept 22, 2015 - “Cancer treatment shouldn’t bankrupt patients” is the gist of an emotional argument put forth by Democratic presidential hopefuls Hillary Clinton and Bernie Sanders.
read article (paid subscription required) 

Provectus Biopharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial to Study PV-10 in Combination with Immune Check Point Inhibitor Pembrolizumab

(Stockhouse) Sept 23, 2015 - Provectus Biopharmaceuticals, Inc. today announced it has completed development of the protocol for Phase1b/2 testing of its investigational cancer drug PV-10 in combination with pembrolizumab in patients with Stage IV melanoma.
read article 

Amgen To Present New Kyprolis® (carfilzomib) Data At 15th International Myeloma Workshop

(CNN Money) Sept 23, 2015 - Additional data from phase 3 ASPIRE trial including age analysis and quality of life results.
read article 

Clovis Oncology Announces Data Presentations At 2015 European Cancer Congress

(Clovis Oncology) Sept 23, 2015 - Three oral presentations and four scientific posters selected for presentation at the European Cancer Congress in Vienna, Austria; rucaparib oral presentation on Tuesday, September 29 to include final outcomes data from full ARIEL2 part 1 population of 206 women with advanced ovarian cancer; clinical updates on rociletinib in various patient subsets with advanced disease.
read corporate press release